Following lethal tox report, Boehringer scraps plans for high-speed development, kills $730M Hanmi deal
Boehringer-Ingelheim decided to abruptly wash its hands of a $730 million cancer drug collaboration with Hanmi after a South Korean ministry linked the therapy to several cases of severe toxicity — one of which left a patient dead. Boehringer confirmed the report in a reply to Endpoints News early Friday afternoon, saying Korean officials had tracked three cases of toxic epidermal necrolysis, which can spur hemorrhaging and respiratory failure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.